2875:TSEToyo Suisan Kaisha, Ltd. Analysis
Data as of 2026-06-14 - not real-time
¥9,846.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Toyo Suisan Kaisha, Ltd. is trading at roughly ¥9,846, a price that sits just above the computed support level of ¥9,789 and well below the analyst consensus target median of ¥12,300, indicating a clear price discount. Technical indicators reinforce this view: the 20‑day SMA of ¥10,639 and 50‑day SMA of ¥10,762 both sit above the market price, while the 200‑day SMA of ¥10,836 suggests the stock is still below its longer‑term average. The RSI of 29.5 places the equity in oversold territory, and the MACD histogram is deeply negative (‑87.5) with a bearish signal line, confirming short‑term downward momentum. Nevertheless, the company’s fundamentals remain solid: a forward PE of about 15×, a price‑to‑book of 1.8×, and a dividend yield near 2.2% with a modest payout ratio of roughly 30% indicate reasonable valuation and cash flow coverage. The balance sheet shows a low debt‑to‑equity of 0.60 and ample cash (¥261.8 bn) relative to debt (¥3.3 bn), supporting dividend sustainability.
Recent material news highlights a shareholder proposal for a ¥36 bn share‑repurchase aimed at accelerating the board’s 15% ROE target, which could tighten the capital structure and provide a modest upside catalyst. However, the stock’s 30‑day volatility of about 24% and a max drawdown of –20% underscore notable price swing risk, especially given the low beta (~0.24) that limits market‑wide hedging benefits.
In summary, the equity appears undervalued relative to consensus targets, with a fair valuation grade, sustainable dividend coverage, but carries medium‑level risk from price volatility and sector‑specific defensive dynamics.
Recent material news highlights a shareholder proposal for a ¥36 bn share‑repurchase aimed at accelerating the board’s 15% ROE target, which could tighten the capital structure and provide a modest upside catalyst. However, the stock’s 30‑day volatility of about 24% and a max drawdown of –20% underscore notable price swing risk, especially given the low beta (~0.24) that limits market‑wide hedging benefits.
In summary, the equity appears undervalued relative to consensus targets, with a fair valuation grade, sustainable dividend coverage, but carries medium‑level risk from price volatility and sector‑specific defensive dynamics.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near technical support
- oversold RSI
- bearish MACD signal
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- fair PE relative to peers
- stable dividend yield
- low debt‑to‑equity
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- price discount to consensus target
- share‑repurchase upside catalyst
- sustainable cash flow and dividend
Key Metrics & Analysis
Financial Health
Revenue Growth19.20%
Profit Margin13.08%
P/E Ratio13.8
ROE13.59%
ROA8.66%
Debt/Equity0.60
P/B Ratio1.8
Op. Cash Flow¥85.2B
Free Cash Flow¥18.0B
Technical Analysis
TrendBearish
RSI29.5
Support¥9,789.00
Resistance¥11,325.00
MA 20¥10,639.35
MA 50¥10,762.64
MA 200¥10,836.17
MACDBearish
VolumeStable
Fear & Greed Index89.86
Valuation
Fair Value¥8,024.64
Target Price¥12,109.09
Upside/Downside22.98%
GradeUndervalued
TypeBlend
Dividend Yield2.23%
Risk Assessment
Beta0.01
Volatility24.21%
Sector RiskLow
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.